Loading...
01/10 23:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong performance in smoke-free products, gross margin expansion, and organic revenue growth. Despite cigarette volume decline, smoke-free products like IQOS and ZYN are driving growth. The Q&A session confirms strong ZYN growth and strategic investments in the U.S., though some uncertainties remain. Overall, positive guidance and strong financial metrics suggest a positive stock price reaction.
Quarterly Smoke-Free Gross Profit More than $3 billion, achieved for the first time, driven by double-digit smoke-free top-line momentum and cost benefits.
Adjusted Group Operating Income Margin Over 43%, the highest in almost 4 years, supported by smoke-free business growth and cost efficiencies.
Adjusted Diluted Earnings Per Share (EPS) $2.24, a 17% year-over-year growth, attributed to strong smoke-free business performance and favorable tax rates.
HTU Adjusted In-Market Sales Growth 9% in Q3, reflecting strong momentum in Europe, Japan, and Global Markets.
Heated Tobacco Unit (HTU) Shipment Growth 15.5% in Q3, driven by strong performance in Europe, Japan, and Global Markets.
ZYN U.S. Offtake Growth 39% in Q3, supported by enhanced marketing and promotional activities.
ZYN U.S. Shipments 37% growth to 205 million cans in Q3, driven by strong performance in the nicotine pouch category.
VEEV Shipments More than doubled year-to-date, with strong performances in Germany, Romania, and Greece.
Organic Top Line Growth 5.9% in Q3, or 7.3% excluding the Indonesia technical impact, driven by positive shipment volumes, strong smoke-free category mix, and pricing.
Adjusted Operating Income (OI) $4.7 billion in Q3, a 7.5% organic growth and 12.4% growth in dollar terms, supported by increasing profitability across smoke-free and combustibles.
Adjusted Diluted EPS Growth 17.3% in Q3, including a currency tailwind of $0.08, reflecting strong financial performance and favorable tax rates.
Organic Net Revenue Growth 7.5% year-to-date, or 9% excluding the Indonesia technical impact, driven by volumes, pricing, and mix.
Adjusted Operating Income Growth 12.5% year-to-date organically, close to 14% in dollar terms, reaching $12.7 billion.
Smoke-Free Volume Growth 16.6% in Q3, driven by strong fundamentals of IQOS, ZYN, and VEEV.
Cigarette Volume Decline 3.2% in Q3, reflecting better-than-expected dynamics in Turkey and Egypt.
Smoke-Free Net Revenue Growth 13.9% organically in Q3, with gross profit growth of 14.8%.
Gross Margin Expansion 170 basis points overall in Q3, reaching 67.9%, a record level since the pandemic recovery of 2021.
Smoke-Free Gross Margin Expansion 360 basis points year-to-date, driven by IQOS, ZYN, and VEEV.
Adjusted Operating Income Margin Expansion 60 basis points organically in Q3, or 120 basis points in dollar terms, reaching 43.1%.
ZYN Global Can Shipment Growth 36% in Q3, with strong growth in the U.S. and international markets.
VEEV Volume Growth 91% in Q3, driven by strong momentum and increasing operating leverage.
Combustible Pricing 8.3% in Q3, contributing to robust performance despite a 3% volume decline.
Smoke-free products: Achieved over $3 billion in quarterly gross profit for the first time, with adjusted group operating income margin of over 43%. Smoke-free products are now commercialized in 100 markets, including the launch of IQOS in Taiwan. Multi-category strategy deployed in 25 markets.
IQOS: Delivered strong gross margin contribution with 15.5% heated tobacco unit shipment growth. Strong momentum in Europe, Japan, and Global Markets.
ZYN: Relaunched commercial activities in the U.S., achieving 39% offtake growth and 37% shipment growth to 205 million cans. International can volumes increased by 27% or over 100% excluding Nordic countries.
VEEV: Total shipments more than doubled year-to-date. Now the #1 closed pod brand in 8 markets, with strong performances in Germany, Romania, and Greece.
Geographic expansion: Smoke-free products commercialized in 100 markets, including Taiwan. ZYN launched in Spain and piloted in Japan. Strong growth in Europe, Japan, and the U.S.
U.S. market: ZYN achieved 39% offtake growth and 37% shipment growth. IQOS 3 pilots continued, awaiting FDA authorization for IQOS ILUMA.
Cost efficiency: On track to deliver $2 billion cost-saving objective over 2024-2026. Gross margin expanded to 67.9%, a record since 2021.
Marketing and investment: Elevated SG&A costs due to investments in IQOS, ZYN, and VEEV. $100 million invested in ZYN's U.S. relaunch activities in Q3.
Multi-category strategy: Deployed in 25 markets to enhance growth. Leveraging IQOS equity to convert more nicotine users.
Dividend increase: Raised dividend for the 18th consecutive year to $5.88 per share, reflecting strong performance and confidence in outlook.
Regulatory Hurdles: The company faces potential challenges from regulatory developments, such as the unfavorable regulatory environment in Poland and the pending FDA authorization for IQOS ILUMA in the U.S. Additionally, the FDA's review process for nicotine pouches could impact the growth of ZYN.
Competitive Pressures: Intensifying competition in Japan and other markets is leading to increased commercial investment and promotional intensity, which could pressure margins and market share.
Supply Chain Disruptions: Earlier supply chain disruptions in Turkey affected cigarette category share, though recovery is underway.
Economic Uncertainties: Currency fluctuations, particularly Euro-dollar movements, could influence the company's leverage ratio and financial performance.
Strategic Execution Risks: The company is heavily investing in marketing and promotional activities, particularly for ZYN in the U.S., which could strain resources if returns on investment are not realized as expected. Additionally, the planned $2 billion cost-saving objective over 2024-2026 requires effective execution to avoid financial strain.
Market Conditions: The U.S. nicotine pouch category is growing rapidly, but the company faces challenges in maintaining its premium pricing for ZYN amidst heightened promotional activities and competition.
Revenue Growth: The company expects organic net revenue growth of 6% to 8% for the full year 2025, driven by positive volumes, smoke-free mix, and pricing. However, growth is likely to be in the lower half of this range due to U.S. investments and other factors.
Smoke-Free Product Growth: Smoke-free shipment volume growth is forecasted at 12% to 14% for 2025, with the lower half of this range being more likely. IQOS HTU shipments are expected to reach close to 38 billion units in Q4, with a full-year growth forecast of 10% to 12% in adjusted IMS.
Operating Income and Margins: The company forecasts double-digit organic operating income growth of 10% to 11.5% for 2025, with strong adjusted operating income margin expansion expected to exceed 40%.
Earnings Per Share (EPS): Adjusted diluted EPS growth is projected at 12% to 13.5% in currency-neutral terms for 2025, translating to 13.5% to 15.1% in dollar terms, including a $0.10 currency tailwind.
Cash Flow: Operating cash flow for 2025 is forecasted to exceed $11.5 billion at prevailing exchange rates, subject to year-end working capital requirements.
Debt and Leverage: The company targets a net debt to EBITDA ratio of around 2x by the end of 2026, with further deleveraging planned for 2025.
Market and Product Expansion: The company plans to continue investing in the growth of its smoke-free products, including IQOS, ZYN, and VEEV, with geographic expansion and innovation in devices and consumables. ZYN is expected to drive significant growth in the U.S. and international markets.
Tax Rate: The adjusted effective tax rate for 2025 is expected to be around 22%, with a higher rate anticipated in Q4.
Q4 Expectations: Q4 is expected to show slower top-line growth, single-digit organic operating income growth, and up to 6% currency-neutral adjusted diluted EPS growth due to shipment dynamics, pricing timing, and higher tax rates.
Dividend Increase: In September, the company raised its dividend for the 18th consecutive year to $5.88 per share, reflecting an 8.9% growth, the largest increase since 2013. This increase was attributed to strong year-to-date performance and confidence in the company's outlook.
The earnings call indicates strong performance in smoke-free products, gross margin expansion, and organic revenue growth. Despite cigarette volume decline, smoke-free products like IQOS and ZYN are driving growth. The Q&A session confirms strong ZYN growth and strategic investments in the U.S., though some uncertainties remain. Overall, positive guidance and strong financial metrics suggest a positive stock price reaction.
The earnings call reveals strong growth in the smoke-free business and ZYN shipments, alongside raised guidance for revenue, operating income, and EBITA. Despite some uncertainties in EU regulations and FDA approvals, the company's strategic initiatives and cost savings bolster a positive outlook. The Q&A session highlights robust growth drivers and confidence in achieving targets, with potential short-term boosts from resumed promotions. Overall, the positive sentiment outweighs the risks, suggesting a likely 2% to 8% stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
